Jazz Pharmaceuticals PLC

1JAZZ

Company Profile

  • Business description

    Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

  • Contact

    Waterloo Road
    Fifth Floor, Waterloo Exchange
    DublinD04 E5W7
    IRL

    T: +353 16347800

    E: [email protected]

    https://www.jazzpharmaceuticals.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    2,800

Stocks News & Analysis

stocks

Nvidia Earnings: No signs of a slowdown in demand for AI chips

A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
stocks

ASX results reaction: WiseTech, Woolies, Sigma and more

A round up of notable stories and reactions as ASX reporting season rolls on.
stocks

WiseTech result disappoints, but the future looks bright

Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,243.009.000.10%
CAC 407,703.9058.70-0.76%
DAX 4023,902.21137.71-0.57%
Dow JONES (US)45,544.8892.02-0.20%
FTSE 1009,187.3429.48-0.32%
HKSE25,077.6278.800.32%
NASDAQ21,455.55249.61-1.15%
Nikkei 22542,718.47110.32-0.26%
NZX 50 Index12,930.7327.650.21%
S&P 5006,460.2641.60-0.64%
S&P/ASX 2008,973.104.100.05%
SSE Composite Index3,857.9314.330.37%

Market Movers